US › Healthcare

Eterna Therapeutics Inc (ERNA)

US · Healthcare · Biotechnology

$2.09-3.69%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-4.0M

EPS

$-3.40

EPS estimate

$-3.30

EPS came in at -3.40 against a street estimate of -3.30 — a miss of 3.0%.

Key statistics

Market cap

$3.4M

Forward P/E

0.0

P/B

1.35

Book value

$2.73

EPS (TTM)

$-13.63

52-week high

$48.00

52-week low

$2.01

50-day MA

$3.89

200-day MA

$9.24

Beta

2.65

Analyst view

Analysts rate Eterna Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $30.00.

Shareholding

Insiders

29.53%

Institutions

2.18%

Largest institutional holders

Fund	Stake
Citadel Advisors Llc	0.93%
Vanguard Fiduciary Trust Co	0.51%
Dauntless Investment Group, LLC	0.37%
Vanguard Capital Management, LLC	0.35%
Tradewinds Capital Management, LLC	0.02%
BlackRock Inc	0.00%
Genworth Financial Wealth Mgmt Inc	0.00%
BNP Paribas Arbitrage, SA	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Eterna Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.